Assignee
CSL Behring Lengnau AG
CH·13 granted patents·9 pending applications·6 citations·filing 2015–2024
Top patents by PatentIndex Score
22 records- 0184US10688157B2Truncated von Willebrand factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2016·Granted Jun 23, 2020·2 cites·23 claims
- 0282US10905747B2Methods for preparing modified von Willebrand factorCSL Behring Lengnau AG·Filed 2020·Granted Feb 2, 2021·1 cites·14 claims
- 0373US10806774B2Mutated truncated von Willebrand FactorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·42 claims
- 0470US10808023B2Mutated von Willebrand factorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·22 claims
- 0568US11564976B2Methods for preparing modified von Willebrand FactorCSL Behring Lengnau AG·Filed 2020·Granted Jan 31, 2023·0 cites·15 claims
- 0662US10253088B2Modified von Willebrand FactorCSL Behring Lengnau AG·Filed 2015·Granted Apr 9, 2019·1 cites·8 claims
- 0762US2025115890A1Improved media for the expression of recombinant vitamin k-dependent proteinsCSL Behring Lengnau AG·Filed 2024·Application pending·0 cites
- 0856US10772936B2Methods for preparing modified von Willebrand factorCSL Behring Lengnau AG·Filed 2016·Granted Sep 15, 2020·0 cites·13 claims
- 0955US11479578B2Protein purification and virus inactivation with alkyl glycosidesCSL Behring Lengnau AG·Filed 2018·Granted Oct 25, 2022·0 cites·33 claims
- 1052US2024293516A1Factor ix subcutaneous administration with enhanced safetyCSL Behring Lengnau AG·Filed 2022·Application pending·0 cites
- 1151US2022389082A1A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viiiCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
- 1244US11141466B2Modulation of FVIII immunogenicity by truncated VWFCSL Behring Lengnau AG·Filed 2018·Granted Oct 12, 2021·0 cites·20 claims
- 1344US2022332847A1RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERSCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
- 1443US11890327B2Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorderCSL Behring Lengnau AG·Filed 2017·Granted Feb 6, 2024·0 cites·23 claims
- 1543US11814421B2Truncated von Willebrand Factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2017·Granted Nov 14, 2023·0 cites·24 claims
- 1643US2022348637A1Polypeptides for inducing tolerance to factor viiiCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
- 1740US12209261B2Media for the expression of recombinant vitamin K-dependent proteinsCSL Behring Lengnau AG·Filed 2016·Granted Jan 28, 2025·0 cites·11 claims
- 1840US2021095006A1RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICACSL Behring Lengnau AG·Filed 2018·Application pending·0 cites
- 1939US2020093901A1Subcutaneous administration of long-acting factor ix in humansCSL Behring Lengnau AG·Filed 2017·Application pending·0 cites
- 2039US2020115436A121-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereofCSL Behring Lengnau AG·Filed 2018·Application pending·0 cites
- 2139US2023025806A1Stable compositions of fc multimersCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
- 2237US11155601B2Modified von Willebrand factor having improved half-lifeCSL Behring Lengnau AG·Filed 2016·Granted Oct 26, 2021·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when CSL Behring Lengnau AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →